257 related articles for article (PubMed ID: 27756693)
21. Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications.
Kim J; Zhang K; Cai W; YorkWilliams S; Ua Cruadhlaoich MAI; Llanes S; Menon V; Poston KL
Neuropsychologia; 2018 Oct; 119():24-33. PubMed ID: 30040957
[TBL] [Abstract][Full Text] [Related]
22. Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state.
Semrau JA; Perlmutter JS; Thoroughman KA
J Neurophysiol; 2014 Jun; 111(12):2675-87. PubMed ID: 24694937
[TBL] [Abstract][Full Text] [Related]
23. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic effects on the implicit processing of distractor objects in Parkinson's disease.
Castiello U; Bonfiglioli C; Peppard RF
Exp Brain Res; 2000 Nov; 135(2):251-8. PubMed ID: 11131510
[TBL] [Abstract][Full Text] [Related]
25. The effects of dopaminergic medication on dynamic decision making in Parkinson's disease.
Osman M; Ryterska A; Karimi K; Tu L; Obeso I; Speekenbrink M; Jahanshahi M
Neuropsychologia; 2014 Jan; 53():157-64. PubMed ID: 24269857
[TBL] [Abstract][Full Text] [Related]
26. Automatic Online Motor Control Is Intact in Parkinson's Disease With and Without Perceptual Awareness.
Merritt KE; Seergobin KN; Mendonça DA; Jenkins ME; Goodale MA; MacDonald PA
eNeuro; 2017; 4(5):. PubMed ID: 29085900
[TBL] [Abstract][Full Text] [Related]
27. Levodopa and the feedback process on set-shifting in Parkinson's disease.
Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
[TBL] [Abstract][Full Text] [Related]
28. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Lange KW; Paul GM; Naumann M; Gsell W
J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
[TBL] [Abstract][Full Text] [Related]
29. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
30. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
[TBL] [Abstract][Full Text] [Related]
31. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
[TBL] [Abstract][Full Text] [Related]
32. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
33. Excitability of the lower-limb area of the motor cortex in Parkinson's disease.
Vacherot F; Attarian S; Eusebio A; Azulay JP
Neurophysiol Clin; 2010 Aug; 40(4):201-8. PubMed ID: 20674816
[TBL] [Abstract][Full Text] [Related]
34. The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.
Suppa A; Bologna M; Conte A; Berardelli A; Fabbrini G
Expert Rev Neurother; 2017 Feb; 17(2):181-192. PubMed ID: 27477028
[TBL] [Abstract][Full Text] [Related]
35. Verbal fluency in Parkinson's disease patients on/off dopamine medication.
Herrera E; Cuetos F; Ribacoba R
Neuropsychologia; 2012 Dec; 50(14):3636-40. PubMed ID: 22995942
[TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
[TBL] [Abstract][Full Text] [Related]
37. Levodopa effect upon functional balance of Parkinson's disease patients.
Nova IC; Perracini MR; Ferraz HB
Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
[TBL] [Abstract][Full Text] [Related]
38. Working memory in Parkinson's disease patients: clinical features and response to levodopa.
Beato R; Levy R; Pillon B; Vidal C; du Montcel ST; Deweer B; Bonnet AM; Houeto JL; Dubois B; Cardoso F
Arq Neuropsiquiatr; 2008 Jun; 66(2A):147-51. PubMed ID: 18545772
[TBL] [Abstract][Full Text] [Related]
39. Cooperative and competitive contexts do not modify the effect of social intention on motor action.
Quesque F; Mignon A; Coello Y
Conscious Cogn; 2017 Nov; 56():91-99. PubMed ID: 28697981
[TBL] [Abstract][Full Text] [Related]
40. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
